Personal profile


Dr. Natasha Anstee completed her PhD in 2015 at The Walter and Eliza Hall Institute of Medical Research where she was supervised by Prof. Suzanne Cory. During her PhD, Dr. Anstee investigated the consequences of overexpression of the prosurvial protein MCL-1 for haemopoiesis, autoimmunity and for the development and treatment of MLL-AF9-induced AML. 

From 2017-2019 Dr. Anstee worked as a Postdoctoral Reseach Fellow at the German Cancer Research Centre (DKFZ) and Heidelberg Institute of Stem Cell Technology and Experimental Medicine (HI-STEM) in the laboratory of Dr. Michael Milsom. Her research was focused on reassessing the concept of haempoietic stem cell self-renewal based on single cell tranplantation outcomes.

In 2020 she joined the Leukemia Research Group, led by A/Prof. Andrew Wei at the Austrlian Centre for Blood Diseases (Monash University), based at The Alfred Hospital. She is in charge of the correlative studies emerging from AML clinical trials led by A/Prof. Wei, with a major focus on tracking MRD using NGS assays as well investigating clonal evolution through single cell technologies.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

External positions

Research Scientist, Alfred Hospital

Research area keywords

  • Stem cells
  • Leukaemia
  • Clonal evolution

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or